We confirmed the primary immunotherapeutic effects of the CSF1R inhibitor in the MMTV-PyMT mammary tumor models by demonstrating that the drug achieves reduction in macrophage accumulation together with tumor growth inhibition. The gene discussed is CSF1R; the disease is breast cancer.